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Abstract
Background: The differential diagnosis between follicular thyroid adenoma and minimal invasive
follicular thyroid carcinoma is often difficult for several reasons. One major aspect is the lack of
typical cytological criteria in well differentiated specimens. New marker molecules, shown by poly-
or monoclonal antibodies proved helpful.
Methods: We performed global gene expression analysis of 12 follicular thyroid tumours (4
follicular adenomas, 4 minimal invasive follicular carcinomas and 4 widely invasive follicular
carcinomas), followed by immunohistochemical staining of 149 cases. The specificity of the antibody
was validated by western blot analysis
Results:  In gene expression analysis QPRT was detected as differently expressed between
follicular thyroid adenoma and follicular thyroid carcinoma. QPRT protein could be detected by
immunohistochemistry in 65% of follicular thyroid carcinomas including minimal invasive variant
and only 22% of follicular adenomas.
Conclusion:  Consequently, QPRT is a potential new marker for the immunohistochemical
screening of follicular thyroid nodules.
Background
Differentiated thyroid carcinomas show an incidence of
approximately 1% of all human malignancies [1]. In the
group of endocrine malignant tumours they form, how-
ever, the largest entity. Differentiated thyroid carcinomas
are a heterogeneous group composed of papillary, follicu-
lar (FTC) and medullary thyroid carcinoma [2]. In con-
trast to papillary carcinoma, which usually can be easily
diagnosed by its characteristic growth pattern und nuclear
features, FTC can appear cytologically identical to follicu-
lar thyroid adenoma (FTA). In these cases only the growth
pattern distinguishes between benign and malignant thy-
roid tumours. According to the grade of invasion, FTC can
be subdivided in widely invasive FTC and minimal inva-
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sive FTC. These show a different clinical behaviour [3].
Histologically, minimal invasive FTC as well as widely
invasive FTC are usually well differentiated tumours, lack-
ing cytological atypia. The diagnosis of FTC is based on
histological findings such as angioinvasion and/or inva-
sion that penetrates the full thickness of the tumour-sur-
rounding capsule [4].
To what extend these criteria are fulfilled in special cases
may remain a matter of interpretation and provides a high
inter- and even intraobserver variability [5,6]. In order to
establish additional criteria for FTC molecular techniques
such as sequencing and FISH [7,8] were applied. These
had limited value in discriminating FTC from FTA. RAS
point mutations were evident in FTC as well as FTA, and
chromosomal rearrangements (PAX8/PPARγ-rearrange-
ment) were seen in some FTC and FTA with a preference
of FTC [9-11].
The aim of our study was the discovery of new helpful
immunohistochemical markers for the detection and def-
inition of FTC.
Methods
Material
Tissue of 4 FTA, 4 minimal invasive FTC and 4 widely
invasive FTC was divided in two parts each. One part of
the specimens was fixed in 4% buffered formalin and
embedded in paraffin. The other part was snapfrozen in
liquid nitrogen and stored at -80°C.
qRT-PCR: Fresh frozen material from 4 FTA and 4 FTC was
used.
Tissue from 149 patients was available for immunohisto-
chemistry for a retrospective study. 77 of these showed
FTA and 72 FTC. Huerthle cell tumours were not included
in this study. Western Blotting was performed by using
fresh frozen tissue of 3 FTC and 3 FTA. The tissue of these
3 FTC was also taken for gene expression analysis.
Moreover, a prospective study of QPRT-expression with
staining of 149 solitary thyroid nodules was undertalen.
Of these 149 nodules, 75 were FTA, 51 nodular goiter, 9
oxyphilic FTA, 7 minimal invasive FTC and 7 others
(Graves' disease, papillary thyroid carcinoma, diffuse
goiter, or no nodule).
All specimen were originally submitted for diagnostic pur-
poses and studied in accordance with national ethical
principles and in compliance with the Helsinki declara-
tion. Informed consent for the use of fresh frozen material
in gene expression analysis was obtained from the
patients. The study was approved by the ethics committee
of the university hospital Frankfurt/Main.
RNA-extraction
RNA-extraction from fresh frozen tissue was performed
using the RNAeasy Kit (Quiagen GmbH, Hilden, Ger-
many) following the manufacturer's instructions. RNA
quantity was measured using GeneQuant II photometer
(Amersham Pharmacia Biotech, San Francisco, USA).
Gene expression analysis
Four biological replicates of FTC and FTA were used for
gene expression profiling. Briefly, DIG-labeled cRNA was
generated using 1 μg total RNA per sample for amplifica-
tion and labeling conducted according to manufacturer's
instructions (Applied Biosystems RT-IVT Labeling Kit
V.2.0 protocol). 10 μg of the DIG-labeled cRNA were
hybridized on Applied Biosystems Human Genome Sur-
vey Microarrays V.2.0 according to manufacturer's instruc-
tions (Applied Biosystems Chemiluminescence Detection
Kit protocol Rev. D). Raw data from our microarray exper-
iments have been deposited in Gene Expression Omni-
bus: http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE15045
Immunohistochemistry
Deparaffinized 5 μm paraffin sections were used for all
immunostainings. For dermatopontin immunostaining
antigen retrieval was performed (30 minutes cooking in
citrate buffer (pH 6.0) in a microwave oven). For QPRT
immunostaining, no antigen retrieval was necessary. The
slides were treated with normal goat serum (4 μg/mL;
Santa Cruz Biotechnology, Heidelberg, Germany), incu-
bated at 4°C overnight applying the primary antibody
dermatopontin (dilution 1:100, polyclonal antibody,
Cat.Nr. 10537-1-AP, ProteinTech Group, Inc., Chicago,
USA) or QPRT (dilution 1:200, clone 5D11, Abnova Cor-
poration, Taipei, Taiwan). The Envision system with alka-
line phosphatase and Fast Red (DAKO, Hamburg,
Germany) was used. Tonsils with follicular hyperplasia
where used as positive controls. For negative controls, no
antibody was added.
The following criteria were applied to evaluate the immu-
nostained sections:In positive cases, at least 10% of
tumour cells had to show a cytoplasmatic immunoreac-
tion. Most positive cases displayed positivity for more
than 50% of the tumour cells. The staining pattern was
heterogen. The percentage of positive cells was estimated
in relation to negative tumour cells.
TaqMan® Quantitative real-time PCR
QPRT expression was analyzed by a quantitative real-time
RT-PCR (qRT-PCR) assay (Hs00204757_m1, Applied bio-
systems, Weiterstadt, Germany). Beta-2-microglobulin
(B2M) was used as endogenous control (4326319E,
Applied Biosystems) for relative quantification. qRT-PCR
was performed using a 96-well tray on the AbiPrism 7900BMC Cancer 2009, 9:93 http://www.biomedcentral.com/1471-2407/9/93
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HT (Applied biosystems). The total reaction volume of 20
μl contained 1 × TaqMan universal Mastermix, 1 μl
primer-probe mix and 5 μl cDNA. The samples were tested
twice as singleplex-PCR. Results were specified as RQ-
value, and calculated with SDS 2.2.1 (Applied biosys-
tems) (RQ = 2-ΔΔCt. ΔΔCt is calculated as difference in ΔCt-
value between the sample and the reference sample)
Western Blot analysis
For western blotting snap frozen tumour tissue was lysed
in 62.5 Tris-HCl, 2% SDS, 1.5% β-mercaptoethanol, 9%
glycerol, 10 μg/ml leupeptin, 10 μg/ml aprotinin and
0.00125% bromophenol blue, cooked 10 min, with inter-
mitting stirring, and cooled on ice.
Cell-lysates were subjected to a 10–20% SDS-PAGE (Cri-
terion™ Pre-Cast Gel, Bio-Rad Laboratories GmbH,
München, Germany) and electrotransferred onto a nitro-
cellulose membrane (Bio-Rad Immuno-Blot™ PVDF, Bio-
Rad). The membranes were incubated with the QPRT anti-
body (dilution 1:1000) at 4°C overnight, followed by
incubation with a horseradish-peroxidase-conjugated
anti-mouse secondary antibody (dilution 1:2000, Code
P0260, DAKO). For signal detection the chemilumines-
cence detection system ECL plus (Amersham Biosciences,
Little Chalfont, UK) was used. Actin (C11, Santa Cruz Bio-
technology) was used as loading control.
Statistics
Statistical analysis was performed with the statistical com-
puting environment R [12]. Additional software packages
(ab1700, rma, multtest) were taken from the Bioconduc-
tor project [13].
Probe level normalization was conducted using the quan-
tile normalization method [14].
Probeset summarization was calculated using the robust
median polish method [15] on the normalized data. For
each probeset an additive robust additive model on the
logarithmic scale (base 2) was fitted across the arrays, con-
sidering the different affinities of the probes via the probe
effect. We used a global filter to reduce the dimension of
the microarray data: We applied an intensity filter (the sig-
nal intensity of a probe set should be above 100 in at least
25 percent of the samples, if the group size is equal) and
a variance filter (the interquartile range of log2 intensities
should be at least 0.5).
p-values were calculated applying the two sample t-test
(assuming equal variances in both groups) to identify
genes that are differentially expressed between the two
groups. We use the False Discovery Rate (FDR) [16] to
account for multiple testing. Also Fold Changes (FC)
between the two groups were calculated for each gene.
Differentially expressed genes were determined with p-
value, FDR and FC criteria.
Unsupervised hierarchical cluster analysis was performed
with the agglomeration method „average“. Manhattan
method is used for the distance measure. Probe sets with
a standard deviation more than one were included in the
clustering. The results of immunohistochemical staining
were analyzed with a Pearson's Chi-Square test, using
SPSS 8.0 (SPSS Inc., Chicago, USA).
Sensitivity is defined as positive stained carcinomas in
relation to all carcinomas included in the study. Specifi-
city is the fraction of carcinomas in all positively immu-
nostained samples.
Results
Gene expression analysis
Gene expression analysis was performed using 4 FTA, 4
widely invasive FTC and 4 minimal invasive FTC. In unsu-
pervised hierarchical clustering 3830 probe sets with a
standard deviation more than one over all samples were
included. The adenomas formed one group in the cluster
analysis (figure 1) whereas widely invasive FTC and min-
imally invasive each FTC clustered together. An exchange
between the two groups occurred once: one widely inva-
sive FTC clustered with the minimal invasive FTC and one
minimal invasive FTC clustered with the widely invasive
FTC. Unexpectedly the widely invasive FTC clustered
closer to the FTA than to the minimal invasive FTC. FTA in
comparison to minimal invasive and widely invasive FTC
differed in 25 genes (FC > 5 or <-5, p-value < 0.05, see
Additional file 1). For further analysis the genes with the
strongest differential expression, namely dermatopontin
(FC 12.6 and 39.5) and quinolinate phosphoribosyltrans-
ferase (QPRT, FC -6.0 and -5.0) were selected.
Immunohistochemistry
Immunohistochemical validation of the results of the
gene expression analysis was performed in a two-step-pro-
cedure: first, both antibodies were tested in a set of 32
probes. According to gene expression analysis, dermat-
opontin should have been positive in FTA and QPRT in
FTC. However, dermatopontin appeared to be of little use
(59% accuracy; 6 out of 17 positive FTA and 8 out of 15
positive FTC). Only QPRT was used with further 117
slides for a second step. Taken together, with QPRT a cor-
rect diagnosis according to our staining was reached in
107 out of 149 cases (72%). The sensitivity was 65% (47/
72), the specificity 73% (47/64). The positive predictive
value was 0,73, the negative predictive value was 0,71.
Divided into subgroups, the sensitivity in minimal inva-
sive FTC (60%) was lower than in widely invasive FTC
(75%). Results are shown in table 1. Figure 2 shows an
example of immunohistochemical staining.BMC Cancer 2009, 9:93 http://www.biomedcentral.com/1471-2407/9/93
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In the prospective study, 59 out of 75 FTA were QPRT-neg-
ative (78,7%), while 6 out of 7 minimal invasive FTC were
positive (85,7%). From the cases with nodular goiter, 14
out of 51 turned out to be positive (27,4%), most cases
showed a focal positivity, often in areas with oxyphilic
metaplasia. In accordance with this observation, oxyphilic
FTA showed a positivity in most of the cases (6 out of 9,
66,7%). The other 7 cases included in this study were
mostly negative (one oxyphilic FTC, two cases with
Graves'disease, one papillary thyroid carcinoma, one dif-
fuse goiter and one thyroid without nodules). Only one
papillary thyroid carcinoma, follicullar variant stained
positive.
Western Blot
Western blotting confirmed the specificity of the QPRT-
antibody. 3 FTA and 3 FTC were used for western blotting.
Only the three FTC, but none of the FTA, showed a band
at 34 kD (Figure 3B).
qRT-PCR
qRT-PCR of FTC compared to FTA showed a ΔΔCt of
10,44 in FTC compared to 0,42 in FTA, indicating a nearly
Unsupervised clustering of 4 follicular adenomas (FTA), 4 minimal invasive follicular carcinomas (FTC) and 4 widely invasive  FTC Figure 1
Unsupervised clustering of 4 follicular adenomas (FTA), 4 minimal invasive follicular carcinomas (FTC) and 4 
widely invasive FTC. The clustering was performed with 3830 genes. Adenomas cluster to one group, which is surprisingly 
located between widely and minimal invasive follicular carcinomas. One of the widely as well as the minimal invasive follicular 
carcinoma is located in the each other group. Red: FTA, green: widely invasive FTC, blue: minimal invasive FTC
Table 1: Tabular list of results of immunohistochemical QPRT 
staining.
Staining
+- T o t a l
FTA 17 60 77
minimal invasive FTC 29 19 48
widely invasive FTC 18 6 24
Total 64 85 149
Pearson Chi-Square = 28,4, p < 0,0001BMC Cancer 2009, 9:93 http://www.biomedcentral.com/1471-2407/9/93
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twenty times higher amount of QPRT-RNA in carcinoma
tissue (Figure 3A).
Discussion
We performed gene expression analysis of 12 follicular
thyroid tumours (4 FTA, 4 minimal invasive FTC and 4
widely invasive FTC) resulting in a list of 25 genes which
differed highly in their FTC and FTA expressions. The most
interesting gene was QPRT showing a significant 5 fold
upregulation in FTC compared to FTA. In further immu-
nohistochemical validation QPRT could be established as
helpful in discriminating between FTA and FTC. In a ret-
rospective study 47 out of 72 FTC were positively immu-
nostained by this antibody. 60 out of 77 FTA were
negative for QPRT. Further validation was performed by
using qRT-PCR and western blotting. Both validation
methods confirmed our immunohistochemical findings.
In an additional prospective study with 149 cases, 78,8%
of FTA were stained negatively. 85,7% of minimal inva-
sive FTC were stained positively with the QPRT-antibody.
The potential value of this marker lies in the screening of
thyroid nodules, with nodules staining positively being
processed intensively.
Representative picture of immunohistochemical staining of FTC (A-C) and FTA (D-F) Figure 2
Representative picture of immunohistochemical staining of FTC (A-C) and FTA (D-F). Carcinoma tissue displays 
a cytoplasmatic staining of the tumour cells, while adenoma tissue remains unstained.
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QPRT is a 34 kD [17] key enzyme in the catabolism of qui-
nolinate in the tryptophan-nicotinamide adenine dinu-
cleotide pathway. Quinolinate is an endogenous
neurotoxin [18], which is non-enzymatically derived from
alpha-amino-beta-carboxymuconate-semialdehyde
(ACMS) [19]. It has been speculated that QPRT activity
increases in response to neurodegenerative events [20].
QPRT has been described in the nucleus and cytoplasma
[21] of cells of the human central nervous system and the
liver [22] and in blood cells (platelets and erythrocytes)
[23]. Gene expression analysis revealed a QPRT upregula-
tion with a fold change of 3,6 in uterine leiomyoma [24].
So far, QPRT has not been linked to other human diseases
besides neurodegenerative disorders. In addition, it is
unknown if QPRT is important in carcinogenesis. Until
now QPRT has not been described in human thyroid tis-
sue.
Different techniques such as global gene expression anal-
ysis and SAGE-analysis have been used to define follicular
thyroid carcinoma (see Additional file 2). [25-30] The
authors cited above validated the established gene expres-
sion or SAGE-results by qRT-PCR. qRT-PCR was also used
as classifier to distinguish between a set of few genes
[26,30] and gene trios [29], which were able to classify
thyroid nodules correctly in between 83 and 96,7%. Two
publications reported additional immunohistochemical
staining based on some factors provided by gene expres-
sion analysis [26,30,31] resulting in 6 new immunohisto-
chemical markers (see Additional file 2).
Of these markers, the two not commercially available
antibodies integral membran proteine 1 (ITM1) and chro-
mosome 1 open reading frame 24 (C1orf24) had the
highest sensitivity of 100% [31]. Damage-inducible tran-
script 3 (DDIT3) and arginase II (ARG2) showed a high
specificity with 85% positivity in carcinomas and only
9,4% positivity in adenomas [26].
Our gene expression results indicated, however, that no
difference in gene expression between three of the four
markers (ARG2, DDIT3 and ITM1), C1orf24 was present
at our gene chip. One reason for this may be the different
methodological approach. Cerutti et al. did SAGE-analysis
of one FTC and one FTA. In contrast, we used the applied
gene expression system at 12 follicular thyroid nodules.
Furthermore, there was no statement of the number of
minimal invasive FTC included in the study, and the total
number of cases used for immunohistochemistry was lim-
ited to27 carcinomas and 22 adenomas.
Other factors obtained by gene expression analysis and
tested immunohistochemically were cyclin D2 (CCND2)
and protein convertase 2 (PCSK2). A combination of
these two factors resulted in a sensitivity of 89,5% and a
specificity of 80,8%.
Both factors were described as downregulated and conse-
quently no immunostaining was found in FTC [30].
PCSK2 is, however, upregulated in FTC in gene expression
analysis in two different studies [26,28]. Our global gene
expression analysis also revealed a significant upregula-
tion of PCSK2 in minimal invasive FTC compared to FTA.
In addition, we found no significant difference in gene
expression of PCSK2 between widely invasive FTC and
FTA.
In several studies immunohistochemical markers for dif-
ferentiating thyroid nodules were defined as independent
from gene expression analysis. HBME-1, galectin-3 and
qRT-PCR (A) and western blot analysis (B) of the 3 FTA and  FTC presented in figure 2 Figure 3
qRT-PCR (A) and western blot analysis (B) of the 3 
FTA and FTC presented in figure 2. In qRT-PCR, carci-
nomas reveal a relative quantity of QPRT-RNA expression 
between 3,65 and 25,18. The relative quantity of QPRT-RNA 
expression in adenomas is between 0,13 and 1,00. In western 
blot analysis, FTC reveal a strong band at 34 kD, while follic-
ular adenomas lack any band. Blotting with actin was per-
formed as loading control. Ad: Adenoma; Ca: Carcinoma.
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CK19 were the markers most frequently referred to in lit-
erature and most commonly used for differentiating
benign from malignant thyroid tumours. These markers
showed, however, a low specificity for FTC. FTC was
described as positive for HBME-1 in between 63 and 88%,
while FTA was positive in 55,6 until 48,6% of the cases.
Galectin-3 showed a positivity between 21 and 64% in
FTC compared to 11 until 2,9% in FTA. CK19 also showed
a low specificity with positivity in FTC in 21–44% and in
FTA in 28,6 and 33% [32,23]. Therefore these markers
seemed unpractical for routine diagnosis.
Our approach differs significantly from other studies in
tissue selection. We grouped minimal invasive FTC from
widely invasive FTC and FTA. Moreover we used only
genes for further analysis, which were significantly differ-
ently regulated in the group of minimal invasive FTC and
widely invasive FTC. Another major difference was the
method used for gene expression. The articles mentioned
above relied on SAGE-analysis, self-designed DNA-micro-
arrays, with a number of genes between 3200 and 7458
[27-29], or affymetrix U95A or 133A oligonucleotid
arrays [25,30]. We used oligonucleotide gene expression
analysis from applied biosystems, which had, to our
knowledge, not been used for analysis of follicular thyroid
carcinoma before. This may explain why there was no
overlap between the genes reported to be differently
expressed as well as the set of genes we found. Another dif-
ference was the way of validating the gene expression
analysis. We focussed on immunohistochemical staining,
using a large set of follicular tumours. Therefore we con-
centrated on genes with high expression differences
between FTC and FTA to find a gene suitable for immuno-
histochemical staining.
Conclusion
In conclusion, gene expression analysis revealed a new
immunohistochemical marker, which may be helpful in
differentiating FTC from FTA. QPRT is a potential useful
marker for immunohistochemical screening analysis of
solitary thyroid nodules. In case of positivity the lesion
should be processed extensively. This procedure probably
reduces the number of misdiagnosed or overlooked min-
imal invasive carcinomas. The sensitivity of the new mon-
oclonal antibody is, however, limited. For this reason,
QPRT as other new markers has the highest diagnostic rel-
evance if it is applied not solitary but in combination.
Additional prospective studies of fine needle aspirates
should be included.
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